Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Naunyn Schmiedebergs Arch Pharmacol
2010 Mar 01;3813:261-70. doi: 10.1007/s00210-009-0454-4.
Show Gene links
Show Anatomy links
The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.
Gierten J, Ficker E, Bloehs R, Schweizer PA, Zitron E, Scholz E, Karle C, Katus HA, Thomas D.
???displayArticle.abstract???
Two-pore-domain (K(2P)) potassium channels mediate background potassium currents, stabilizing resting membrane potential and expediting action potential repolarization. In the heart, K(2P)3.1 (TASK-1) channels are implicated in the cardiac plateau current, I ( KP ). Class III antiarrhythmic drugs target cardiac K(+) currents, resulting in action potential prolongation and suppression of atrial and ventricular arrhythmias. The objective of this study was to investigate acute effects of the class III antiarrhythmic drug amiodarone on human K(2P)3.1 channels. Potassium currents were recorded from Xenopus oocytes using the two-microelectrode voltage clamp technique. Amiodarone produced concentration-dependent inhibition of hK(2P)3.1 currents (IC(50) = 0.40 microM) with maximum current reduction of 58.1%. Open rectification properties that are characteristic to hK(2P)3.1 currents were not altered by amiodarone. Channels were blocked in open and closed states in reverse frequency-dependent manner. hK(2P)3.1 channel inhibition was voltage-independent at voltages between -40 and +60 mV. Modulation of protein kinase C activity by amiodarone does not contribute to hK(2P)3.1 current reduction, as pre-treatment with the protein kinase C inhibitor, staurosporine, did not affect amiodarone block. Amiodarone is an inhibitor of cardiac hK(2P)3.1 background channels. Amiodarone blockade of hK(2P)3.1 may cause prolongation of cardiac repolarization and action potential duration in patients with high individual plasma concentrations, possibly contributing to the antiarrhythmic efficacy of the class III drug.
Backx,
Background potassium current active during the plateau of the action potential in guinea pig ventricular myocytes.
1993, Pubmed
Backx,
Background potassium current active during the plateau of the action potential in guinea pig ventricular myocytes.
1993,
Pubmed Barbuti,
Block of the background K(+) channel TASK-1 contributes to arrhythmogenic effects of platelet-activating factor.
2002,
Pubmed Bayliss,
The TASK family: two-pore domain background K+ channels.
2003,
Pubmed Besana,
Activation of protein kinase C epsilon inhibits the two-pore domain K+ channel, TASK-1, inducing repolarization abnormalities in cardiac ventricular myocytes.
2004,
Pubmed Duprat,
TASK, a human background K+ channel to sense external pH variations near physiological pH.
1997,
Pubmed
,
Xenbase Futamura,
Effect of amiodarone on cytokine release and on enzyme activities of mouse alveolar macrophages, bone marrow macrophages, and blood monocytes.
1996,
Pubmed Gierten,
Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein.
2008,
Pubmed
,
Xenbase Goldstein,
Potassium leak channels and the KCNK family of two-P-domain subunits.
2001,
Pubmed Haffajee,
Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience.
1983,
Pubmed Hohnloser,
Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.
1994,
Pubmed Honoré,
An intracellular proton sensor commands lipid- and mechano-gating of the K(+) channel TREK-1.
2002,
Pubmed Kathofer,
The novel antiarrhythmic drug dronedarone: comparison with amiodarone.
2005,
Pubmed Kiehn,
Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels.
1999,
Pubmed
,
Xenbase Kindler,
Local anesthetic inhibition of baseline potassium channels with two pore domains in tandem.
1999,
Pubmed
,
Xenbase Lalevée,
Control of cardiac rhythm by ORK1, a Drosophila two-pore domain potassium channel.
2006,
Pubmed Latini,
Clinical pharmacokinetics of amiodarone.
1984,
Pubmed Leonoudakis,
An open rectifier potassium channel with two pore domains in tandem cloned from rat cerebellum.
1998,
Pubmed
,
Xenbase Lopes,
Proton block and voltage gating are potassium-dependent in the cardiac leak channel Kcnk3.
2000,
Pubmed
,
Xenbase Maingret,
The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1.
2001,
Pubmed Marbán,
Cardiac channelopathies.
2002,
Pubmed Naccarelli,
Amiodarone: clinical trials.
2000,
Pubmed Nerbonne,
Molecular physiology of cardiac repolarization.
2005,
Pubmed Patel,
Properties and modulation of mammalian 2P domain K+ channels.
2001,
Pubmed Podrid,
Amiodarone: reevaluation of an old drug.
1995,
Pubmed Putzke,
The acid-sensitive potassium channel TASK-1 in rat cardiac muscle.
2007,
Pubmed
,
Xenbase Silver,
Inhibition of calmodulin and protein kinase C by amiodarone and other class III antiarrhythmic agents.
1989,
Pubmed Sirois,
The TASK-1 two-pore domain K+ channel is a molecular substrate for neuronal effects of inhalation anesthetics.
2000,
Pubmed Thomas,
Alternative translation initiation in rat brain yields K2P2.1 potassium channels permeable to sodium.
2008,
Pubmed
,
Xenbase Thomas,
Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A.
1999,
Pubmed
,
Xenbase Veronese,
Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method.
1988,
Pubmed Zimetbaum,
Amiodarone for atrial fibrillation.
2007,
Pubmed
